Use access key #2 to skip to page content.

Manifest (93.05)

Recs

1

Our Festivus Five for the Restivus!

December 22, 2016 – Comments (0) | RELATED TICKERS: TEVA , MLNX , VOD

Happy Festivus, Fool Nation.  This week's study selections are looking for a 52-week Festivus Miracle but they're grounded in solid long-term return forecasts and top shelf quality.  We believe there are some Feats of Strength champions in here.  https://expectingalpha.com/2016/12/22/festivus-five-12232016/

Recs

1

Haystack Rewards: Great Again

December 10, 2016 – Comments (0) | RELATED TICKERS: MLAB , VIVO , MELI

Our annual Best Small Companies list has delivered approximately 20% returns for 2016 and 2015 while the Wilshire 5000 checked in at 4% or so.  We believe that a blend of faster-growing, smaller, promising companies (think Hidden Gems or RuleBreakers) combines with a core of blue chip stalwarts to round out an effective all-of-the-above portfolio.  The 2016 list is here:https://expectingalpha.com/2016/12/10/best-small-companies-2016/  The tracking dashboard is available via https://www.manifestinvesting.com/dashboards/public/best-small-2016  Shop and study at will.  Commence January Effect!   [more]

Recs

1

Favorite Screens: Launch Pad Logic 2017

December 09, 2016 – Comments (0) | RELATED TICKERS: GSK , BUD , AMZN

We'll add GlaxoSmithKline (GSK) to our long-term CAPS tracking portfolio as a result of this screening technique that seeks the highest year-over-year (2017 vs. 2016) EPS changes -- while sticking to the Best Companies.  https://expectingalpha.com/2016/12/09/favorite-screens-launch-pad-2017/

Recs

1

Screening by Escape Velocity

December 08, 2016 – Comments (0) | RELATED TICKERS: ABBV

Every year, we run a stock selection challenge at www.manifestinvesting.com that starts and ends on Groundhog Day, year over year.  There's an individual and group competition.  A group from St. Louis (Broad Assets) has won 3-of-the-last-4 group championships and it appears they favor stocks with good long term prospects in combination with "launch pad earnings" for this year vs. last year.  For more, see: https://expectingalpha.com/2016/12/08/fave-five-escape-velocity/ We're adding Abbvie (ABBV) as part of this week's hunt.  [more]

Recs

1

Teva Pharma (TEVA)

December 01, 2016 – Comments (0) | RELATED TICKERS: TEVA

The Street is wrecked over the Actavis integration and Copaxone competition.  Teva Pharma (TEVA) is a gorilla and the 3-5 year outlook is pretty good.  The Value Line low total return forecast is approximately 15% and TEVA landed at the top of of this week's Fave Five: https://expectingalpha.com/2016/12/01/fave-five-1222016-2/  [more]

Featured Broker Partners


Advertisement